Roche: negligible increase in pharmaceuticals

Published By Datamonitor

Roche: making Pegasys fly in Europe

Roche can now market Pegaysys to EU hepatitis C sufferers. It should win market share from Schering-Plough's Peg Intron, which hit EU markets last year. But hepatitis C is increasingly being treated with combined pegylated interferon and ribavirin - so until Roche gains approval for its ribavirin variant, Copegus, Roche will not be able to fully displace Schering's patient capture.

Published By Datamonitor

Roche: improved potential for MabThera

A phase III clinical trial of Roche's [ROCZg.VX] MabThera (rituximab) in patients below 60 years of age with aggressive non-Hodgkin's lymphoma was halted early because its primary efficacy endpoint was met two years earlier than expected. These trial results are likely to consolidate MabThera's position as the best-selling innovative agent for cancer.

Published By Datamonitor

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor

Roche: HIV announcement to dispel pipeline fears

Published By Datamonitor

Roche: cautious start to metabolic syndrome development

JTT-705, which Roche is to license from Japan Tobacco, is a novel anti-dyslipidemic that will further enhance the company's cardiovascular risk factor offering. This latest move could ultimately place Roche in a potentially advantageous position in the growing metabolic syndrome market, though it marks only the start of a long process to increase its currently meager offering in this field.

Published By Datamonitor

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor

Roche: building a strong hepatitis C portfolio

Published By Datamonitor

Roche/Schering-Plough: competing in drug markets, not courts

Published By Datamonitor

Roche/GSK: monthly formulation puts Boniva in pole position

The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.

Published By Datamonitor